Journey Medical (DERM) to Release Earnings on Thursday

Journey Medical (NASDAQ:DERM) is expected to be posting its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Journey Medical to post earnings of ($0.22) per share for the quarter.

Journey Medical Stock Up 0.4 %

DERM opened at $5.33 on Wednesday. The business’s 50-day simple moving average is $4.74 and its 200-day simple moving average is $5.10. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.03 and a current ratio of 1.38. Journey Medical has a one year low of $2.85 and a one year high of $6.89. The stock has a market capitalization of $111.34 million, a P/E ratio of -5.67 and a beta of 0.97.

Insider Transactions at Journey Medical

In other news, CEO Claude Maraoui sold 49,271 shares of Journey Medical stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $5.01, for a total transaction of $246,847.71. Following the sale, the chief executive officer now owns 2,003,147 shares in the company, valued at approximately $10,035,766.47. The trade was a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders have sold 105,831 shares of company stock worth $536,622. Corporate insiders own 13.16% of the company’s stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.